EASL Clinical Practice Guidelines on hepatitis delta virus

J Hepatol. 2023 Aug;79(2):433-460. doi: 10.1016/j.jhep.2023.05.001. Epub 2023 Jun 24.

Abstract

Hepatitis D virus (HDV) is a defective virus that requires the hepatitis B virus to complete its life cycle and cause liver damage in humans. HDV is responsible for rare acute and chronic liver diseases and is considered the most aggressive hepatitis virus. Acute infection can cause acute liver failure, while persistent infection typically causes a severe form of chronic hepatitis which is associated with rapid and frequent progression to cirrhosis and its end-stage complications, hepatic decompensation and hepatocellular carcinoma. Major diagnostic and therapeutic innovations prompted the EASL Governing Board to commission specific Clinical Practice Guidelines on the identification, virologic and clinical characterisation, prognostic assessment, and appropriate clinical and therapeutic management of HDV-infected individuals.

Keywords: CHD treatment; Chronic hepatitis D; HDV; HDV RNA; anti-HDV.

Publication types

  • Practice Guideline
  • Research Support, N.I.H., Intramural

MeSH terms

  • Carcinoma, Hepatocellular* / diagnosis
  • Carcinoma, Hepatocellular* / etiology
  • Carcinoma, Hepatocellular* / therapy
  • Hepatitis B virus
  • Hepatitis D* / complications
  • Hepatitis D* / diagnosis
  • Hepatitis D* / therapy
  • Hepatitis Delta Virus
  • Humans
  • Liver Neoplasms* / diagnosis
  • Liver Neoplasms* / etiology
  • Liver Neoplasms* / therapy